Abstract:
The invention relates to compounds of formula (I) or a salt or solvate thereof, wherein: x represents 0 or 1; y represents 0 or 1; R 1 and R 2 independently represent -C 1-9 alkyleneC 1-6 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms and wherein said R 1 and/or R 2 moiety is optionally interrupted by an ether link, processes for their preparation, use of said compounds in the preparation of pharmaceutical aerosol formulations and said formulations.
Abstract:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
Abstract:
There are provided according to the invention compounds of the formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R represents (CO)xC1-9alkyl or (CO)xC1-9fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R and R independently represent C1-3alkyl or hydrogen. There are also provided pharmaceutical aerosol formulations employing said compounds as suspension stabilising agents.
Abstract translation:根据本发明提供式(I)化合物或其盐或溶剂化物,其中:n表示1至6的整数; N表示1〜15的整数, R 1表示(CO)x C 1-9烷基或(CO)x C 1-9氟烷基,该氟烷基部分含有至少1个氟原子和不多于3个连续的全氟化碳原子,其中x表示0或1; R 2和R 3独立地表示C 1-3烷基或氢。 还提供了使用所述化合物作为悬浮稳定剂的药物气溶胶制剂。
Abstract:
The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
Abstract:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
Abstract:
Compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.
Abstract:
There are provided according to the invention compounds of formula (I) or salts or solvate thereof, wherein:n and N independently represent an integer 2 to 12;m1 and m2 independently represent an integer 1 to 15; and R1 and R2 independently represent -(CO)xC1-9 alkyl or -(CO)xC1-9 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1. The invention includes uses of said compounds and processes for their preparation.
Abstract translation:根据本发明提供了式(I)的化合物或其盐或溶剂合物,其中:n和N独立地表示2至12的整数; m 1和m 2独立地表示1至15的整数 ; 并且R 1和R 2独立地表示 - (CO)x C 1-9烷基或 - (CO)x C 1-9氟代烷基,其中氟代烷基部分含有至少1个氟原子和不多于3个连续的全氟化碳原子,其中x代表0或1。 包括所述化合物的用途及其制备方法。 p>
Abstract:
A pharmaceutical aerosol formulation comprising a particulate medicament, one or more fluorocarbon or hydrogen-containing fluorocarbon propellants and a compound of the general formula (I) or a salt or solvate thereof, wherein A represents a straight chain C 1 - 16 alkylene substituted by n groups of formula B; n represents an integer 1 to 3; and B independently represents C 1 - 4 fluoroalkylC 0 - 6 alkylene-, C 1 - 4 fluoroalkylC 0 - 6 alkylene-O-, or C 1 - 4 alkylC 0 - 6 alkylene-O- wherein at least one substituent of formula B contains at least one fluorine atom and each C 1 - 4 fluoroalkyl- moiety contains one or more fluorine atoms but not more than 3 consecutive perfluorinated carbon atoms. The invention also extends to uses of compounds of formula (I) and certain novel compounds within the definition of formula (I).
Abstract:
There are provided according to the invention compounds of the formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R 1 represents (CO) x C 1-9 alkyl or (CO) x C 1-9 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R 2 and R 3 independently represent C 1-3 alkyl or hydrogen. There are also provided pharmaceutical aerosol formulations employing said compounds as suspension stabilising agents.